Abstract: The invention relates to a poly[?-cyanoacrylate] hydrolyzate, a preparation method and an application thereof, belonging to the field of pharmaceutical and chemical industry. A main technical solution is as follows: provided is a poly[?-cyanoacrylate] hydrolyzate having a chemical formula: CH2—CRCOOHn, wherein R=—CN or —COOH. Poly[2-cyanoacrylic acid] provided by the present invention is dispersed in water to prepare the negatively charged microsphere, that is, to obtain the new blank embolic microsphere, the particle size of the microsphere can be adjusted in a micron-scale range, and the microsphere have a deformation function to pass through a vascular with a specific shape, which can tightly embolize the vascular to avoid ectopic embolism caused by falling off; poly[2-carboxyacrylic acid] can be used for preparing a new nano-drug carrier, improving the curative effect of the carried drug on diseased tissues and reduce the toxic and side effects of the carried drug on normal tissues.

Abstract: Drug delivery devices and methods are provided for administering gemcitabine to a patient in need of treatment of bladder cancer by intravesically administering gemcitabine into the bladder of the patient to achieve a sustained concentration of the gemcitabine in urine in the bladder sufficient to produce a therapeutically effective concentration of the gemcitabine in the tissues of the bladder. In embodiments, the local administration into the patient's bladder is at a mean average amount of from 1 mg/day to about 300 mg/day of the gemcitabine (FBE).

Abstract: The present invention relates to zirconium silicate compositions having a lead content that is below 0.6 ppm and methods of manufacturing zirconium silicate at reactor volumes exceeding 200-L with a lead content below 1.1 ppm. The lead content of the zirconium silicate of this invention are within the levels that are considered acceptable for extended use given the dose requirements for zirconium silicate.

Abstract: An adhesive composition described herein comprises an aqueous solvent; and a population of first nanoparticles dispersed in the aqueous solvent, the first nanoparticles comprising a negative or positive charge, and an average size in three dimensions of 1 nm to 1000 nm. In some embodiments, a population of second nanoparticles is dispersed in the aqueous solvent, the second nanoparticles comprises a negative or positive charge opposite the charge of the population of first nanoparticles. In some embodiments, the population of first nanoparticles comprise an average first size in three dimensions, and the population of second nanoparticles comprise an average second size in three dimensions that is different from the average first size of the first nanoparticles.

Abstract: A controlled-release multilayer microparticle containing a pharmaceutically active compound, which is intended for oral administration or direct administration in the stomach, which may be done using a liquid pharmaceutical composition containing the microparticle. The microparticle may include: a core that includes the pharmaceutically active compound, which may be pramipexole; a controlled-release intermediate coating layer; and an outmost external protection coating layer surrounding the controlled-release intermediate coating layer. The external protection coating layer may include a mixture of: a hydrophilic gastro-soluble component which is insoluble in aqueous media at a pH of between 6.5 and 7.5; and a hydrophobic and/or insoluble component.

Abstract: A lipid nanoparticles manufacturing chip includes a mixer unit for forming a mixed solution by mixing a first raw material containing an active ingredient and a second raw material containing a lipid, a dilution unit that is connected to the mixer unit and dilutes the mixed solution using a diluent solution to make a diluted mixed solution, and a concentration unit connected to the dilution unit and for obtaining a concentrated solution by concentrating lipid nanoparticles (LNP) from the diluted mixed solution.

Abstract: A hybrid encapsulate formulation obtained by mixing a starch/fragrance emulsion with a core-shell capsule suspension is provided as is a method of using the formulation in a personal care product, a beauty care product, a fabric care product, a home care product, a personal hygiene product, an oral care product and a method for releasing an encapsulated fragrance by moisture, shear, or a combination thereof.

Abstract: A method of making Cu—Ag3PO4 nanoparticles is provided. The method includes forming a mixture of at least one silver salt, at least one phosphate salt, and at least one copper (II) salt. The method further includes dissolving the mixture in water. The method further includes sonicating the mixture. The method further includes precipitating the Cu—Ag3PO4 nanoparticles or “nanoparticles”. The copper is present in the nanoparticles in an amount of 2 to 23 weight percent (wt. %) based on the total weight of the Cu—Ag3PO4. The nanoparticles of the present disclosure find application in treating cervical cancer, and colorectal cancer. The nanoparticles may also be used in photodegrading environmental pollutants.

Abstract: A formulation is disclosed for use in wound healing. The formulation may include hypochlorous acid, a silicone polymer or blend thereof, sodium phosphate, hydrochloric acid, and sodium magnesium silicate. Methods of using and making the wound healing formulation are also disclosed.

Abstract: Multi-coated nanoparticles including multiple coating layers of chitosan and polyglutamic acid, composition for skin care including the same, and method of manufacturing the same are provided. The nanoparticles have a liposome core layer and coating layers. The core layer includes a bioactive particle and a core hydrogel. Not only is it easy to mass-produce, but also has the effect of steadily releasing bioactive particles for a long period of time due to its high sealing rate and high stability.

Abstract: A method of making Cu—Ag3PO4 nanoparticles is provided. The method includes forming a mixture of at least one silver salt, at least one phosphate salt, and at least one copper (II) salt. The method further includes dissolving the mixture in water. The method further includes sonicating the mixture. The method further includes precipitating the Cu—Ag3PO4 nanoparticles or “nanoparticles”. The copper is present in the nanoparticles in an amount of 2 to 23 weight percent (wt. %) based on the total weight of the Cu—Ag3PO4. The nanoparticles of the present disclosure find application in treating cervical cancer, and colorectal cancer. The nanoparticles may also be used in photodegrading environmental pollutants.

Abstract: The present invention concerns polymer particles made from poly(lactic-co-glycolic acid) (PLGA) polymer, poly(lactic-co-glycolic acid)-polyethylene glycol-poly(lactic-co-glycolic acid) (PLGA-PEG-PLGA) copolymer, or the mixture of same, combined with hyaluronic acid molecules or hyaluronic acid salts, and the method for preparing same. The present invention also concerns injectable pharmaceutical or cosmetic compositions comprising such polymer particles, the method for preparing such compositions, and the use thereof for medical purposes, in particular for the prevention and/or treatment of musculoskeletal diseases, diseases and traumatic conditions of the skin, oral disorders, vaginal mucosa dryness and urinary infections or cystitis, dryness of the eye membrane and eye infections, obesity, and the use of same to combat ageing of the skin and/or for repairing the dermal tissue (mesotherapy).

Abstract: Silver and titanium oxide nanoparticles produced with Fomes fomentarius or Fomitopsis pinicola aqueous extracts and methods for treating bacterial infections or cancer using them.

Abstract: Provided is a core-shell structure having an excellent immediate effect in transdermal absorption of an active ingredient. A core-shell structure comprising a core portion containing an active ingredient, and a shell portion containing a surfactant having an HLB value of 4 to 14, the core portion being solid, and the surfactant containing a saturated hydrocarbon group having 7 to 15 carbon atoms or an unsaturated hydrocarbon group having 7 to 17 carbon atoms.

Abstract: A method of making Cu—Ag3PO4 nanoparticles is provided. The method includes forming a mixture of at least one silver salt, at least one phosphate salt, and at least one copper (II) salt. The method further includes dissolving the mixture in water. The method further includes sonicating the mixture. The method further includes precipitating the Cu—Ag3PO4 nanoparticles or “nanoparticles”. The copper is present in the nanoparticles in an amount of 2 to 23 weight percent (wt. %) based on the total weight of the Cu—Ag3PO4. The nanoparticles of the present disclosure find application in treating cervical cancer, and colorectal cancer. The nanoparticles may also be used in photodegrading environmental pollutants.

Abstract: The invention pertains to a method for treating a neoplasm, such as colorectal cancer, using hollow silica spheres (“HSS”). It also is directed to a method for making uncalcined HSS, calcined HSS from which phenyl groups have been removed, and HSS incorporating particles of Fe3O4, as well as compositions containing HSS.

Abstract: The invention pertains to a method for treating a neoplasm, such as colorectal cancer, using hollow silica spheres (“HSS”). It also is directed to a method for making uncalcined HSS, calcined HSS from which phenyl groups have been removed, and HSS incorporating particles of Fe3O4, as well as compositions containing HSS.

Abstract: The invention pertains to a method for treating a neoplasm, such as colorectal cancer, using hollow silica spheres (“HSS”). It also is directed to a method for making uncalcined HSS, calcined HSS from which phenyl groups have been removed, and HSS incorporating particles of Fe3O4, as well as compositions containing HSS.

Abstract: A method of making Cu—Ag3PO4 nanoparticles is provided. The method includes forming a mixture of at least one silver salt, at least one phosphate salt, and at least one copper (II) salt. The method further includes dissolving the mixture in water. The method further includes sonicating the mixture. The method further includes precipitating the Cu—Ag3PO4 nanoparticles or “nanoparticles”. The copper is present in the nanoparticles in an amount of 2 to 23 weight percent (wt. %) based on the total weight of the Cu—Ag3PO4. The nanoparticles of the present disclosure find application in treating cervical cancer, and colorectal cancer. The nanoparticles may also be used in photodegrading environmental pollutants.

Abstract: The preparation method of a starch-based double-loaded functional nanoparticle includes: performing restrictive hydrolysis treatment on egg high-density lipoprotein using proteases to obtain the polypeptide; performing self-assembling on a mixed system containing the polypeptide and quercetin under the alkaline condition to form a micelle nanoparticle; performing covalent grafting reaction on a mixed system containing the micelle nanoparticle and anthocyanin under the alkaline condition to form a graft; and electrostatically compounding carboxymethyl dextrin with the graft to obtain the starch-based double-loaded functional nanoparticle. In the preparation method, raw materials derived from natural sources are used, and the self-assembled colloid nanoparticle with good properties can be obtained by adjusting the pH without any organic reagents.